Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 782-785

  Tanaka, Rie ^a   Hanabusa, Hideji ^b   Kinai, Ei ^b   Hasegawa, Naoki ^a   Negishi, Masayoshi ^a   Kato, Shingo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ogikubo Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ;

ARTICLE; CELL ISOLATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

ANTI-HIV AGENTS; BENZOXAZINES; CHROMATOGRAPHY, GAS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; REVERSE TRANSCRIPTASE INHIBITORS; TANDEM MASS SPECTROMETRY;

EID: 38649112298     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01613-06     Document Type: Article

References (10)

1. Almond, L. M., P. G. Hoggard, D. Edirisinghe, S. H. Khoo, and D. J. Back. 2005. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J. Antimicrob. Chemother. 56:738-744.
2. Colombo, S., A. Beguin, A. Telenti, J. Biollaz, T. Buclin, B. Rochat, and L. A. Decosterd. 2005. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 819:259-276.
3. Csajka, C., C. Marzolini, K. Fattinger, L. A. Décosterd, J. Fellay, A. Telenti, J. Biollaz, and T. Buclin. 2003. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 73:20-30.
4. Ford, J., S. H. Khoo, and D. J. Back. 2004. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54:982-990.
5. Gao, W.-Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 90:8925-8928.
6. Jones, K., P. G. Bray, S. H. Khoo, R. A. Davey, E. R. Meaden, S. A. Ward, and D. J. Back. 2001. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15:1353-1358.
7. Jones, K., P. G. Hoggard, S. D. Sales, S. Khoo, R. Davey, and D. J. Back. 2001. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15:675-681.
8. Khoo, S. H., P. G. Hoggard, I. Williams, E. R. Meaden, P. Newton, E. G. Wilkins, A. Smith, J. F. Tjia, J. Lloyd, K. Jones, N. Beeching, P. Carey, B. Peters, and D. J. Back. 2002. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob. Agents Chemother. 46:3228-3235.
9. Marzolini, C., A. Telenti, L. A. Decosterd, G. Greub, J. Biollaz, and T. Buclin. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75.
10. Rotger, M., S. Colombo, H. Furrer, G. Bleiber, T. Buclin, B. L. Lee, O. Keiser, J. Biollaz, L. Décosterd, A. Telenti, and the Swiss HIV Cohort Study. 2005. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15:1-5.